Eledon Pharmaceuticals Inc (NASDAQ:ELDN) has a beta value of 0.77 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $350.44M, closed the last trade at $5.30 per share which meant it gained $0.65 on the day or 13.98% during that session. The ELDN stock price is 10.19% off its 52-week high price of $4.76 and 79.81% above the 52-week low of $1.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.61 million shares traded. The 3-month trading volume is 280.46K shares.
The consensus among analysts is that Eledon Pharmaceuticals Inc (ELDN) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) trade information
Sporting 13.98% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ELDN stock price touched $5.30 or saw a rise of 4.33%. Year-to-date, Eledon Pharmaceuticals Inc shares have moved 194.44%, while the 5-day performance has seen it change 56.34%. Over the past 30 days, the shares of Eledon Pharmaceuticals Inc (NASDAQ:ELDN) have changed 107.84%. Short interest in the company has seen 0.14 million shares shorted with days to cover at 2.2.
Eledon Pharmaceuticals Inc (ELDN) estimates and forecasts
Figures show that Eledon Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 119.92% over the past 6 months, with this year growth rate of 7.32%, compared to 17.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.97% over the past 5 years.
ELDN Dividends
Eledon Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Eledon Pharmaceuticals Inc (NASDAQ:ELDN)’s Major holders
Insiders own 0.05% of the company shares, while shares held by institutions stand at 32.13% with a share float percentage of 32.15%. Investors are also buoyed by the number of investors in a company, with Eledon Pharmaceuticals Inc having a total of 37.0 institutions that hold shares in the company. The top two institutional holders are BVF INC/IL with over 6.29 million shares worth more than $16.61 million. As of 2024-06-30, BVF INC/IL held 20.985% of shares outstanding.
The other major institutional holder is ARMISTICE CAPITAL, LLC, with the holding of over 2.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.17 million and represent 7.7894% of shares outstanding.
